BAM15

What it is

BAM15 came in 2014 from a screening that was meant to solve a laboratory problem. Anyone wanting to measure the maximal respiratory capacity of mitochondria needs an uncoupler, and the commonly used candidates FCCP and 2,4-dinitrophenol also depolarize the cell membrane, inhibit mitochondria and are cytotoxic. This distorts measurements and makes the window between effective and toxic narrow.

The search for a cleaner alternative yielded BAM15, an oxadiazolopyrazine: at the same potency as FCCP, a higher maximal respiration rate, lower cytotoxicity, no depolarization of the plasma membrane. The first proof of efficacy in animals was not a metabolic experiment but acute kidney injury after ischemia in the mouse. Only afterwards did the laboratory tool become a candidate against obesity.

How it is supposed to work

The respiratory chain pumps protons out of the mitochondrial matrix; ATP synthase lets them flow back and turns this into ATP. A protonophore opens a second return path: respiration runs faster, more nutrients are oxidized, and part of the energy becomes heat. The body needs more fuel for the same output. That is why the class is regarded as a weight-loss principle, and that is why it is risky.

Two details make BAM15 interesting. First, the tissue distribution: in mice it accumulates mainly in fat tissue, hardly in skeletal muscle — that would explain why lean mass was preserved. Second, the dependence on the energy-sensing kinase AMPK, which according to cell experiments is needed for the sustained nutrient uptake and for tolerability. An uncoupler is therefore not just a hole in the membrane; it sets off an adaptation program.

What was measured in mice

The most revealing part of the experiments is the reversal, not the prevention. After 4 weeks on a Western diet, the animals had more than 20 percent more body mass and three times the fat mass. Only then did treatment begin, for 5 weeks. At the end of the 9 weeks, the treated animals weighed 15 percent less than the control group, with the same calorie intake and no difference in fat-free mass. Triglycerides and cholesterol in the feces did not differ, so the loss was not due to poorer fat absorption.

A second group independently arrived at the same picture: 3 weeks of treatment; from day 9 body weight was below control, and on day 20 the difference was 7.5 grams. Decisive for the safety question: oxygen consumption and total energy expenditure rose, body temperature did not. The half-life is 1.7 to 3 hours, which is why it was given via the food in the long-term experiments.

The comparison that says the most

Individual studies say little about how a substance stands within its class. A 2025 study made up for this and compared 15 structurally unrelated uncouplers. BAM15 was the only substance that improved all core values at the same time in the animal part, and in doing so it beat a calorie restriction of 35 percent. The next best substance improved blood sugar but let body weight and liver fat rise.

Even more interesting is the comparison with what already exists. In female db/db mice, BAM15, semaglutide, rosiglitazone, niclosamide ethanolamine and calorie restriction were pitted against each other: for body weight and liver fat, BAM15 and calorie restriction were ahead; for glucose tolerance, BAM15, semaglutide and rosiglitazone. Another experiment combined both: semaglutide together with the uncoupler lowered body fat and liver triglycerides, which no single treatment achieved. That is the real idea of the class: appetite and calorie efficiency are two levers.

What has been studied beyond the scales

The second line of research has nothing to do with weight loss. In the mouse sepsis model, BAM15 reduced mortality and kidney injury, even when given only 12 hours after induction, via fewer mitochondrial reactive oxygen species and less released mitochondrial DNA. In fruit flies, BAM15 extended lifespan by 9 percent on a normal diet and by 25 percent on a high-fat diet. A preprint in 24-month-old mice found restored muscle strength after 8 weeks, but only in males.

The distinction that matters

2,4-Dinitrophenol is the reason for this class’s bad name: marketed as a slimming agent in the 1930s, banned by the FDA in 1938, back since the 2000s as an illegal fat burner, with deaths. A 2026 case report describes why the poisoning is so hard to control: more carbon dioxide makes the tissue more acidic, more acidic tissue takes up more substance, and hyperthermia, acidosis and hyperkalemia follow. In the case that survived, the effect persisted with a functional half-life of 4.9 days.

BAM15 is chemically something different, and the differences have been measured: no depolarization of the plasma membrane, no rise in temperature in mice, unremarkable liver and kidney markers. In the scene, this is turned into a safe DNP. The data do not support this step, because it concerns humans, and nothing has been measured there. A 2025 study of two large bodybuilding forums shows the practice: BAM15 is regarded there as a low-risk alternative, and a video guide to self-synthesis together with its comment section has increased the willingness to self-experiment. What is in circulation accordingly does not come from controlled manufacturing.

What the studies show

First description 2014

A screening looked for protonophores that leave the plasma membrane untouched. BAM15 met this: the same potency as FCCP, a higher maximal respiration rate in cultured cells, less cytotoxicity. In animals it protected dose-dependently against acute kidney injury after ischemia. The primary endpoint was pharmacological characterization, not a clinical benefit.

Reversal of existing obesity (2020)

Mice on a Western diet for 4 weeks, then 5 weeks with or without BAM15 in the food, 21 animals in the analysis. Result after 9 weeks: 15 percent lower body weight with the same calorie intake, unchanged fat-free mass, unchanged fat excretion in the feces, better insulin action in clamp experiments. Oral bioavailability was 67 percent, the maximal plasma concentration 8.2 micromoles per liter, and the half-life 1.7 hours.

The class comparison (2025)

Of 15 uncouplers, the five best were tested in db/db mice for 4 weeks, divided into 11 feeding groups, against a calorie restriction of 35 percent. Only BAM15 improved all core values at the same time; the HbA1c of the control animals rose from 6 to 8 percent, while under BAM15 it was at the 4 percent of the healthy animals, and the insulin resistance index HOMA-IR was up to 50 percent lower.

Where the data stop

The break is sharp: there is not a single study in humans. A query of the trial registries returns no relevant entry on BAM15, not even for the search term mitochondrial uncoupler. This means pharmacokinetics, tolerability data and any dose-response relationship in humans are missing. This applies to the whole class: even the uncoupler OPC-163493, deliberately developed to be liver-selective and for which animal toxicology in rat, dog and monkey has been published, has no clinical study in the registry — and there the target organs were the liver, blood vessels or kidney depending on the species.

Two caveats belong here. The longevity finding comes from the fruit fly, not from a mammal. And the muscle study in old mice is a preprint without peer review with a sex-dependent result: in females, the mitochondrial values did not improve. Anyone reading the numbers on fat loss should also bear in mind that they come from continuous intake via the food.

Status, approval and legal

BAM15 is not an approved medicine in Germany, the EU or the US, and no clinical trial is registered. It cannot be legally marketed as a food supplement: a synthetic substance without a history of consumption would be a novel food in the EU and would need authorization under the Novel Food Regulation, which does not exist. BAM15 is traded as a research chemical not intended for human use. That is why no amounts are given here: dosage information is prohibited for unapproved substances, and the values from the animal studies are study facts, not instructions. In sport, BAM15 is banned: it is not named in the WADA Prohibited List 2026, so the section for substances without approval by a governmental health authority applies.

Safety

Nothing has been studied in humans, so nothing reliable can be said about side effects, interactions and upper limits. In mice, body temperature, lean mass and the plasma markers for liver and kidney damage remained unremarkable, and tolerability depended on AMPK — both animal data. The real risk of the class is the energy expenditure itself: any substance that generates heat adds to fever, heat, hard exercise and fluid loss, and there are no data on this for BAM15. Added to this is the quality problem: what is in circulation as a research chemical or from self-synthesis has no verified information on identity, purity and content.

Sources

• Kenwood et al., Mol Metab 2014 – first description of BAM15
• Alexopoulos et al., Nat Commun 2020 – reversal of obesity and insulin resistance in mice
• Axelrod et al., EMBO Mol Med 2020 – energy expenditure, AMPK, body temperature
• Shah et al., Mol Metab 2025 – 15 uncouplers in direct comparison
• Chen et al., Biochim Biophys Acta Mol Basis Dis 2024 – BAM15 versus semaglutide and rosiglitazone
• Chen et al., Clin Sci 2024 – semaglutide together with an uncoupler
• Tsuji et al., J Clin Invest 2023 – sepsis and kidney injury in the mouse model
• Taylor et al., Aging Cell 2024 – lifespan in fruit flies
• Inoue et al., EXCLI J 2022 – animal toxicology of the uncoupler OPC-163493
• Lindeman et al., Toxicol Rep 2026 – poisoning cases with 2,4-dinitrophenol